Track topics on Twitter Track topics that are important to you
Innovation Pharmaceuticals has entered a licensing agreement with Italy's Alfasigma for international rights to Brilacidin's -More-
Innovation Pharmaceuticals Inc. licensed Alfasigma SPA global rights to develop and commercialize locally-administered brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis...
Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma S.à r.l. In early 2019, ZELNORM was approved for reintroduction by the FDA for the treatment o...
Alfasigma's Zelnorm, or tegaserod, is being reintroduced in the market after passing a safety review done by the FDA and the -More-
ZELNORM approved by FDA in March 2019 after thorough safety review Alfasigma USA has begun national reintroduction of ZELNORM to prescribers ZELNORM now widely available through wholesale channe...
Alfasigma USA, Inc. is the American affiliate of Alfasigma, a leading Italian pharmaceutical company. Alfasigma is present in more than 90 countries, with a workforce of around 3,000 people and 5 man...
We have published hundreds of Alfasigma USA, Inc. news stories on BioPortfolio along with dozens of Alfasigma USA, Inc. Clinical Trials and PubMed Articles about Alfasigma USA, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alfasigma USA, Inc. Companies in our database. You can also find out about relevant Alfasigma USA, Inc. Drugs and Medications on this site too.